MetaCap

ABVC BioPharma Inc. (ABVC)

NASDAQ: ABVCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.8663-0.0137 (-1.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABVC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$23.37M
EPS (TTM)
-$0.20
52-week range
0.707 – 2.87
Day range
0.85 – 0.917
Volume / Avg
39.05K / 81.92K
Beta
—

52-week range

$0.707$2.87

ABVC stock today

ABVC BioPharma (ABVC) closed at $0.8663 on Nov 20, down 1.56% (-$0.0137), versus the S&P 500's 3.70% decline. Trading was light, with 39.05K shares changing hands, about 48% of the average daily volume. At this level, ABVC sits near the bottom of its 52-week range of $0.707 to $2.87: 69.8% below the high, set on Nov 28, 2025 and 22.5% above the low.

ABVC is down 59.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.8%. ABVC BioPharma has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ABVC BioPharma

Company profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Uttam Yashwant Patil Ph.D.
Headquarters
Fremont, CA
Employees
16

Financial highlights

Full financials

In fiscal 2025, ABVC BioPharma generated $296,000 in revenue, down 41.9% from fiscal 2024, its first annual decline since 2023. ABVC BioPharma reported a net loss of $7.9 million, compared with a loss of $4.9 million a year earlier. Operating margin was -2416.0%.

ABVC BioPharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$296.00K$509.59K$152.43K$969.78K$355.80K
Growth-41.91%+234.31%-84.28%+172.57%-26.34%
Net income$-7.91M$-4.90M$-7.79M$-16.42M$-12.84M
EPS (diluted)$-0.39$-0.42$-1.80$-5.19$-0.51

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.04 vs —

ABVC BioPharma peers

Health Care sector
ABVC peer companies
CompanyPrice% ChgMarket capCompare
SCYXSCYNEXIS Inc.2.38-8.64%$23.69Mvs ABVC
LITSLite Strategy Inc.0.8026-4.03%$23.99Mvs ABVC
IXHLIncannex Healthcare Inc.1.86+6.90%$23.34Mvs ABVC
RMTIRockwell Medical Inc.5.82-7.03%$23.12Mvs ABVC
IMMPImmutep Limited ADR3.11-9.06%$22.92Mvs ABVC
CRVOCervoMed Inc.1.46+9.77%$22.09Mvs ABVC
BCTXBriaCell Therapeutics Corp.3.06-3.32%$26.72Mvs ABVC
TELOTelomir Pharmaceuticals Inc.0.364-17.24%$26.82Mvs ABVC

Indexes, lists and sector

ABVC BioPharma stock FAQ

What is ABVC BioPharma's stock price today?

ABVC last traded at $0.8663 as of Nov 20, 4:00 PM EST, down 1.56% on the day. Prices are delayed at least 15 minutes.

Does ABVC BioPharma pay a dividend?

No. ABVC BioPharma does not currently pay a regular cash dividend.

Who is ABVC BioPharma's CEO?

Dr. Uttam Yashwant Patil Ph.D. is the chief executive officer of ABVC BioPharma Inc., which has about 16 employees.

Has ABVC ever split its stock?

Yes. The most recent ABVC stock split was a 1-for-10 split on Jul 25, 2023, one of 6 splits on record.

What is the ABVC 52-week high?

The 52-week high for ABVC is $2.87 and the 52-week low is $0.707. The stock is currently 69.8% below its high.

Compare ABVC